STK11 and melanoma: Loss-of-function mutations in components of the interferon signaling pathway, such as JAK1/2, have been also identified as examples of primary resistance to ICI in melanoma [89], including upregulation of PD-L1 [95,96], loss of PTEN [97,98], loss-of-function mutations of STK11/LKB1 [99,100], activation of c-Myc [101], activation of the WNT/b-catenin pathway [102], and alterations in the chromatin regulator PBAF [103,104].